Search - tctmd.com

Displaying 1 - 10 of 10

Sort: Relevancy | Date

Three Common Biomarkers Closely Tied to Women’s 30-Year Risk of CV Events

News Conference News ESC 2024

Three Common Biomarkers Closely Tied to Women’s 30-Year Risk of CV Events

August 31, 2024

COP-AF: Colchicine Doesn’t Cut Post-Op AF or Myocardial Injury

News Conference News ESC 2023

COP-AF: Colchicine Doesn’t Cut Post-Op AF or Myocardial Injury

Michael O'Riordan

August 25, 2023

COVID-PACT: Full-Dose Anticoagulation Improves Outcomes in Critical COVID-19

News Conference News ESC 2022

COVID-PACT: Full-Dose Anticoagulation Improves Outcomes in Critical COVID-19

September 01, 2022

‘Hot’ Plaque on Noninvasive PET May Presage MI, CV Death: PRE18FFIR

News Conference News ESC 2022

‘Hot’ Plaque on Noninvasive PET May Presage MI, CV Death: PRE18FFIR

August 28, 2022

Colchicine in STEMI Fails to Reduce Infarct Size: COVERT-MI

News Daily News ESC 2021

Colchicine in STEMI Fails to Reduce Infarct Size: COVERT-MI

August 26, 2021

LoDoCo2: Colchicine Protective in Large RCT of Chronic Coronary Disease

News Conference News ESC 2020

LoDoCo2: Colchicine Protective in Large RCT of Chronic Coronary Disease

August 31, 2020

Under Pressure: PRECISION Substudy Shows Adverse BP Effects of Ibuprofen

News Conference News ESC 2017

Under Pressure: PRECISION Substudy Shows Adverse BP Effects of Ibuprofen

August 30, 2017

Anti-Inflammatory Therapy with Canakinumab for Atherosclerotic Disease

Presentation ESC 2017

Anti-Inflammatory Therapy with Canakinumab for Atherosclerotic Disease

Presenter: Paul M. Ridker

August 27, 2017

CANTOS: Anti-inflammatory Agent Canakinumab Modestly Reduces Major CVD Events

News Conference News ESC 2017

CANTOS: Anti-inflammatory Agent Canakinumab Modestly Reduces Major CVD Events

Michael O'Riordan

August 27, 2017

News Conference News ESC 2015

NSAIDs Plus Anticoagulants a Bad Combination

September 01, 2015

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.